Hutchmed (China) Limited

Director's Dealing • Oct 5, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 0968D

Hutchison China Meditech Limited

05 October 2018

Appointment of HSBC Bank plc as Joint Corporate Broker in London

London: Friday, October 5, 2018: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that it has appointed HSBC Bank plc as its joint Corporate Broker in London with immediate effect. Panmure Gordon (UK) Limited will continue to act as joint Corporate Broker in London and Nominated Advisor to Chi-Med in London in respect of the AIM rules.

About Chi‑Med

Chi‑Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products.  Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market.  Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.

Chi‑Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1).  For more information, please visit: www.chi‑med.com.

Forward‑Looking Statements

This announcement contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see Chi-Med's filings with the U.S. Securities and Exchange Commission and on AIM. Chi-Med undertakes no obligation to update or revise the information contained in this announcement, whether as a result of new information, future events or circumstances or otherwise.

CONTACTS

##### Investor Enquiries
Mark Lee, Senior Vice President, Corporate Finance & Development	+852 2121 8200
David Dible, Citigate Dewe Rogerson	+44 7967 566 919 (Mobile) [email protected]
Xuan Yang, Solebury Trout	+1 (415) 971 9412 (Mobile) [email protected]
##### Media Enquiries
UK & Europe - Anthony Carlisle, Citigate Dewe Rogerson	+44 7973 611 888 (Mobile) [email protected]
Americas - Brad Miles, Solebury Trout	+1 (917) 570 7340 (Mobile) [email protected]
Hong Kong & Asia ex-China - Joseph Chi Lo, Brunswick	+852 9850 5033 (Mobile) [email protected]
Mainland China - Sam Shen, Edelman	+86 1367 179 1029 (Mobile) [email protected]
##### Nominated Advisor
Richard Gray / Andrew Potts, Panmure Gordon (UK) Limited	+44 (20) 7886 2500

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

APPEASESEDEPFEF